Serum markers of Inflammatory Bowel Disease: A literature review

Siti Muchayat Purnamaningsih

Siti Muchayat Purnamaningsih
Departement of Clinical Pathology and Laboratory Medicine, Faculty of Medicine, Gadjah Mada University Jalan Kesehatan, Sekip Utara, Yogyakarta 55281, Indonesia. Email: [email protected]
Online First: August 08, 2018 | Cite this Article
Purnamaningsih, S. 2018. Serum markers of Inflammatory Bowel Disease: A literature review. Bali Medical Journal 7(2). DOI:10.15562/bmj.v7i2.887

Background: The diagnosis, prognosis, assessment of disease activity and severity, as well as the outcome of therapy of inflammatory bowel disease (IBD), Crohn’s disease (CD), and ulcerative colitis (UC), remain a challenge for physicians treating this disorder. For each of these aspects, there is no single gold standard test or examination. Endoscopy accompanied by histology examination can confirm the diagnosis of IBD. Laboratory markers have been investigated in IBD for diagnostic and differential diagnostic purposes, assessment of disease activity and risk of complications, prediction of relapse, and for monitoring the effect of therapy. Objective: This article provides a review of the literature regarding IBD with the recommendation of prominent markers that can be used for diagnosing and monitoring the disease. Conclusion: C-reactive protein is an acute phase reactant which is best used to assess inflammation in IBD. Fecal calprotectin and lactoferrin are reliable fecal markers to monitor disease activity. The combination of serological marker P-ANCA and ASCA can be used to diagnose CD. In clinical practice, Crohn's Disease Activity Index (CDAI) is used as the primary tool for evaluating IBD. 


Bing XIA., Crusius JBA, Meuwissen SGM, Pena AS. Inflammatory bowel disease: definition, epidemiology, etiologic aspects, and immunogenetic studies. WJG. 1998;4(5):446-458

Danese S, Fiocchi C. Ulcerative Colitis. N Engl J Med. 2011. 365:1713­25

Wyeth J. Crohn’s disease and ulcerative colitis. BPJ. Issue 16: 34-38

Vermeire S, Van Assche G, Rutgeerts P. Recent advances in clinical practice laboratory. Laboratory markers in IBD: useful, magic, or unnecessary toys?. GUT. 2006. 55: 426-431

Paduchova Z, Durackova Z. Fecal calprotectin as a promising marker of inflammatory diseases. Bratisl Lek Listy. 2009. 110 (10): 598-602

Bamias G, Nyce MR, Rue SA, Cominelli F. New Concepts in the Pathophysiology of Inflammatory Bowel Disease. Ann Intern Med. 2005. 143:895-904

Anonymous. Crohn’s Disease. Available at Disease + wikipedia

Weiss G, Gasche C. Pathogenesis and treatment of anemia in inflammatory bowel disease. Haematologica. 2010. 95(2): 175-178

Oustamanolakis P, Koutroubakis IE, Messaritakis I, Malliaraki N, Sfiridaki A, Kouroumalis EA. Serum hepcidin and prohepcidin concentrationsin inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2011 Mar. 23(3):262-8

Bergamaschi G, et al. Serum hepcidin in inflammatory bowel diseases: biological and clinical significance. Inflamm Bowel Dis. 2013.. 19(10):2166-72

Vermeire S, Assche GV, Rutgeerts P. C-Reactive Protein as a Marker for InflammatoryBowel Disease.Inflamm Bowel Dis. 2004. 10 (5): 661-665

Vieira A et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Research Notes. 2009. 2(221): 1-7

Turkay C, Kasapoglu B. Noninvasive methods in evaluation of inflammatory bowel disease: where do we stand now? An update. CLINICS. 2010. 65 (2): 221-31

Bossuyt X. Serologic Markers in Inflammatory Bowel Disease. Clinical Chemistry. 2006. 52 (2): 171–181

Kaul A, Hutfless S, Liu L, Marohn MR, Li X, Bayless TM. Serum Anti-glycan Antibody Biomarkers for Inflammatory Bowel Disease Diagnosis and Progression: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2011. 000:000–000

Xie Q, Gan HT. Controversies about the use of serological markers in diagnosis of inflammatory bowel disease.World J Gastroenterol . 2010. 16(2): 279-280

Song WB, et al. Soluble intercellular adhesion molecule-1, D-lactate and diamine oxidase in patients with inflammatory bowel disease. World J Gastroenterol. 2009. 15(31): 3916-3919

Herfarth H. A Reassessment of the CDAI as an Index of Crohn’s Disease. AGAPerspektif. 2013. April/ May, 9 (2): 4,6

Cohen CD. Should Mucosal healing Be used Instead?. AGA Perspektif. 2013. April/May, 9(2): 5,7

Schroeder KW et al. Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis. N Engl J Med. 1987. 317:1625-9

Article Views      : 0
PDF Downloads : 0